A Study of Efavirenz in Combination With Stavudine and Didanosine

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dupont Merck
• Treatments: Didanosine; Efavirenz; Stavudine

Criteria

Inclusion Criteria

Patients must have:

• Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml.

• A life expectancy of at least 12 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Current bilateral peripheral neuropathy greater than or equal to Grade 2.

• Any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values).

• Any clinically significant disease (other than HIV infection) or clinically significant findings during screening of medical history or physical examination.

• Any malignancy that requires systemic therapy.

• Proven or suspected acute hepatitis due to any cause.

• Recurrent episodes of moderate to severe diarrhea, or vomiting lasting more than 4 days within 3 months prior to dosing.

• Active AIDS-defining opportunistic infection or disease.

Concurrent Medication:

Excluded:

Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine.

Patients with the following prior conditions are excluded:

• History of acute or chronic pancreatitis.

• Life expectancy less than 12 months.

• Difficulty in swallowing capsules/tablets.

• Hypersensitivity to any component of the formulation of efavirenz, stavudine, or didanosine.

Prior Medication:

Excluded:

• Any other experimental drug within 30 days of introducing study treatment.

• Vaccination within 3 weeks of screening visit.

• Interferon started within 30 days of initiating study treatment.

• Prior antiretroviral therapy.

Risk Behavior:

Excluded:

• Current alcohol or illicit drug use which would interfere with compliance with dosing schedule and protocol evaluations.